NCT07674134Recruiting
Comparison of Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Comparison of Morning Versus Evening Oral Administration of a JAK Inhibitor in Rheumatoid Arthritis
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response. The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 18 Jun 2026
- Start date
- Apr 2024
- Primary completion date
- Nov 2026
- Lead sponsor
- Centre Hospitalier Princesse Grace
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07674134
What you commit to
- Study type: Observational
- Planned participants: 90
- From Apr 2024 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Not stable dose of corticosteroids in the 4 weeks preceding enrollment
- Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment
- Prior treatment with a JAK inhibitor
Other
- No contraindication to a bDMARD
- Patient unable to be followed-up in the study during 6 months
- Minors or adults under guardianship or curatorship, or deprived of their liberty
- Pregnant or breastfeeding patient
- Patient refusing to use an effective method of contraception for the duration of the study
- Person not affiliated with a social security scheme.
Who the study is looking for
- Patient aged over 18 years
- Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
- Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
- Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Princesse Grace Coordinator of this site? Confirm its status | Monaco | Monaco | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.